Highly selective drug combination for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine

A. F. Sobrero, R. E. Handschumacher, J. R. Bertino

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In the preceding companion paper, we describe a human colon carcinoma cell line that is resistant in vitro to 5-fluoro-2'-deoxyuridine by virtue of impaired nucleoside transport. Two drug combinations, methotrexate:hypoxanthine:thymidine (dThd) and 5,8-dideazaisofolic acid:dThd, selectively kill these resistant cells with no effect on the sensitive cell population. As little as 0.3 μM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 μM hypoxanthine fully protected sensitive cells from >99% methotrexate-induced cell lethality. In contrast, when resistant cells were exposed to these drugs, they were not protected by dThd, or by the combination dThd:hypoxanthine, in concentrations up to 300 times higher than those necessary to prevent sensitive cell kill. Thus, it may be possible to protect normal renewal tissues while obtaining selective tumor cell kill with these two drug combinations in patients whose colon carcinoma cells are resistant to 5-fluoro-2'-deoxyuridine by virtue of defective transport.

Original languageEnglish
Pages (from-to)3161-3163
Number of pages3
JournalCancer Research
Volume45
Issue number7
Publication statusPublished - 1985

Fingerprint

Drug Combinations
Colonic Neoplasms
Hypoxanthine
Methotrexate
Colon
In Vitro Techniques
5-fluoro-2'-deoxyuridine
Carcinoma
Vulnerable Populations
Nucleosides
Thymidine
Cell Line
Acids

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Highly selective drug combination for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine. / Sobrero, A. F.; Handschumacher, R. E.; Bertino, J. R.

In: Cancer Research, Vol. 45, No. 7, 1985, p. 3161-3163.

Research output: Contribution to journalArticle

@article{2b3e921540e24484b06ca1fc9659d3f5,
title = "Highly selective drug combination for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine",
abstract = "In the preceding companion paper, we describe a human colon carcinoma cell line that is resistant in vitro to 5-fluoro-2'-deoxyuridine by virtue of impaired nucleoside transport. Two drug combinations, methotrexate:hypoxanthine:thymidine (dThd) and 5,8-dideazaisofolic acid:dThd, selectively kill these resistant cells with no effect on the sensitive cell population. As little as 0.3 μM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80{\%} lethality in unprotected cells and the same concentration of dThd in combination with 100 μM hypoxanthine fully protected sensitive cells from >99{\%} methotrexate-induced cell lethality. In contrast, when resistant cells were exposed to these drugs, they were not protected by dThd, or by the combination dThd:hypoxanthine, in concentrations up to 300 times higher than those necessary to prevent sensitive cell kill. Thus, it may be possible to protect normal renewal tissues while obtaining selective tumor cell kill with these two drug combinations in patients whose colon carcinoma cells are resistant to 5-fluoro-2'-deoxyuridine by virtue of defective transport.",
author = "Sobrero, {A. F.} and Handschumacher, {R. E.} and Bertino, {J. R.}",
year = "1985",
language = "English",
volume = "45",
pages = "3161--3163",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Highly selective drug combination for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine

AU - Sobrero, A. F.

AU - Handschumacher, R. E.

AU - Bertino, J. R.

PY - 1985

Y1 - 1985

N2 - In the preceding companion paper, we describe a human colon carcinoma cell line that is resistant in vitro to 5-fluoro-2'-deoxyuridine by virtue of impaired nucleoside transport. Two drug combinations, methotrexate:hypoxanthine:thymidine (dThd) and 5,8-dideazaisofolic acid:dThd, selectively kill these resistant cells with no effect on the sensitive cell population. As little as 0.3 μM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 μM hypoxanthine fully protected sensitive cells from >99% methotrexate-induced cell lethality. In contrast, when resistant cells were exposed to these drugs, they were not protected by dThd, or by the combination dThd:hypoxanthine, in concentrations up to 300 times higher than those necessary to prevent sensitive cell kill. Thus, it may be possible to protect normal renewal tissues while obtaining selective tumor cell kill with these two drug combinations in patients whose colon carcinoma cells are resistant to 5-fluoro-2'-deoxyuridine by virtue of defective transport.

AB - In the preceding companion paper, we describe a human colon carcinoma cell line that is resistant in vitro to 5-fluoro-2'-deoxyuridine by virtue of impaired nucleoside transport. Two drug combinations, methotrexate:hypoxanthine:thymidine (dThd) and 5,8-dideazaisofolic acid:dThd, selectively kill these resistant cells with no effect on the sensitive cell population. As little as 0.3 μM dThd was sufficient to completely protect sensitive cells from 5-fluoro-2'-deoxyuridine, and 5,8-dideazaisofolic acid at concentrations that produced over 80% lethality in unprotected cells and the same concentration of dThd in combination with 100 μM hypoxanthine fully protected sensitive cells from >99% methotrexate-induced cell lethality. In contrast, when resistant cells were exposed to these drugs, they were not protected by dThd, or by the combination dThd:hypoxanthine, in concentrations up to 300 times higher than those necessary to prevent sensitive cell kill. Thus, it may be possible to protect normal renewal tissues while obtaining selective tumor cell kill with these two drug combinations in patients whose colon carcinoma cells are resistant to 5-fluoro-2'-deoxyuridine by virtue of defective transport.

UR - http://www.scopus.com/inward/record.url?scp=0021879633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021879633&partnerID=8YFLogxK

M3 - Article

C2 - 3159475

AN - SCOPUS:0021879633

VL - 45

SP - 3161

EP - 3163

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 7

ER -